Immunome Inc., a biotechnology company specializing in targeted cancer therapies, announced on July 1, 2025, that its Compensation Committee granted inducement awards in the form of non-statutory stock options to eight new employees. These options are part of the Company's 2024 Inducement Plan and involve a total of 125,500 shares of common stock. Each stock option is priced at $8.47 per share, reflecting the closing sales price on the grant date. The vesting schedule requires 25% of the shares to vest after one year, with the remaining shares vesting monthly over the following 36 months, contingent on the employees' ongoing service with the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.